Chromosome News and Research

Latest Chromosome News and Research

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Genomic Health, Inc. today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer.

16 Dec 2009

Study may help in treating sex differentiation disorders in children

Is it a boy or a girl? Expecting parents may be accustomed to this question, but contrary to what they may think, the answer doesn't depend solely on their child's sex chromosomes.

11 Dec 2009

Nobel Prize discovery opens new perspectives for detection and prevention of age-related diseases

This year's Nobel Prize in Physiology or Medicine was awarded to three American scientists Elizabeth Blackburn, Carol Greider and Jack Szostak for the discovery of "how chromosomes are protected by telomeres and the enzyme telomerase”. The research contributed to the understanding of how telomeres protect chromosomes from degradation and identified telomerase, the enzyme that preserves telomere length and integrity.

11 Dec 2009

Researchers discover new explanation for differences in severity of mental illness in males

Researchers have discovered a new explanation for differences in the severity of mental illness in males. The more excess copies of a certain gene, the more serious the handicap. The genetic defect is situated on the X-chromosome; and it is suspected that it is the amount of copies of the GDI1 gene that is responsible.

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

Enzo Biochem and Ikonisys sign agreement to market molecular-based cervical cancer test

Enzo Biochem, Inc. announced today that its Enzo Clinical Lab division has entered into an exclusive marketing partnership covering the States of New York and New Jersey with privately-owned Ikonisys, Inc., of New Haven, CT, relating to Ikonisys’ proprietary oncoFISH® cervical test, a laboratory developed test for cervical cancer prevention.

10 Dec 2009

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

In a large clinical trial, nilotinib demonstrated greater efficacy over the current gold standard treatment, imatinib, in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase.

9 Dec 2009

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Transgenomic, Inc. announced today the launch of its SURVEYOR Scan K-RAS kit, the first in a family of mutation detection kits the company plans to offer featuring its proprietary SURVEYOR Nuclease and WAVE® HS DHPLC platform. SURVEYOR Scan technology is a novel approach to mutation detection that uses a PCR amplification reaction and hybridization to form heteroduplex DNA molecules in samples with K-RAS mutation.

9 Dec 2009

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

The National Fragile X Foundation has awarded a translational research seed grant of $100,000 to Dr. Randi J. Hagerman at the UC Davis M.I.N.D. Institute in California for a study of minocycline in the treatment of children with fragile X syndrome (FXS). Hagerman is an internationally recognized clinician and clinical researcher on FXS, the most common cause of inherited mental impairment.

8 Dec 2009

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

ARIAD Pharmaceuticals, Inc. today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers.

8 Dec 2009

New genetic approach may hold promise for sickle cell disease

A new genetic approach to treating sickle cell disease is showing promising results in mice, report researchers from Children's Hospital Boston. By inactivating a gene they previously discovered to be important in the laboratory, they were able to boost production of a healthy fetal form of hemoglobin in the mice, potentially compensating for the defective adult hemoglobin that causes red blood cells to "sickle" and obstruct blood flow.

8 Dec 2009

Animal study demonstrates how whole chromosome changes cause cancer

Mayo Clinic researchers have proven the longstanding theory that changes in the number of whole chromosomes -- called aneuploidy -- can cause cancer by eliminating tumor suppressor genes.

8 Dec 2009

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current therapies, researchers from The University of Texas M. D. Anderson Cancer Center report today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today updated clinical data showing that Omapro™ (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

7 Dec 2009

New approach to protein misfolding may lead to novel therapies for a number of diseases

In an encouraging new development, a team led by Scripps Research Institute scientists has restored partial function to lung cells collected from patients with cystic fibrosis. While there is still much work to be done before the therapy can be tested in humans, the discovery opens the door to a new class of therapies for this and a host of other chronic diseases.

7 Dec 2009

New findings may yield more effective therapies for infants with blood cancer

Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse with another gene to drive an often-fatal form of leukemia in infants. By more accurately defining specific partner genes, researchers expect to better predict which infants may benefit from particular treatments.

7 Dec 2009

New study reveals genetic alteration can lead to severe childhood obesity

Scientists in Cambridge have discovered that the loss of a key segment of DNA can lead to severe childhood obesity. This is the first study to show that this kind of genetic alteration can cause obesity. The results are published today in Nature.

6 Dec 2009

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

IMF to stage presentation on multiple myeloma at ASH annual meeting

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians—today said presentations at the annual meeting of the American Society of Hematology (ASH) will cover all stages of multiple myeloma, a major milestone in treating this and related cancers.

4 Dec 2009

Chromosome News and Research

Latest Chromosome News and Research

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Study may help in treating sex differentiation disorders in children

Nobel Prize discovery opens new perspectives for detection and prevention of age-related diseases

Researchers discover new explanation for differences in severity of mental illness in males

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Enzo Biochem and Ikonisys sign agreement to market molecular-based cervical cancer test

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

New genetic approach may hold promise for sickle cell disease

Animal study demonstrates how whole chromosome changes cause cancer

Phase II clinical trial results reveal positive effects of omacetaxine against CML

ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting

New approach to protein misfolding may lead to novel therapies for a number of diseases

New findings may yield more effective therapies for infants with blood cancer

New study reveals genetic alteration can lead to severe childhood obesity

New treatment options for leukemia and myeloproliferative disorders introduced

IMF to stage presentation on multiple myeloma at ASH annual meeting

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chromosome News and Research

Latest Chromosome News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in